geld als water schreef op 15 mei 2013 20:42:
Outlook 2013 and beyond
•Ruconest BLA submitted to US FDA (April 2013)
•Acceptance for review by FDA triggers US$5M milestone
•First US commercial sale triggers US$20M milestone
•Proceeds from US commercialisation by SNTS
•30%- 40% of Ruconest net sales
•Up to US$45 million in sales related milestones
•Expansion of rhC1INH franchise
-Prophylaxis of HAE
-Acute pancreatitis
-Ischemia Reperfusion Injury
•Leverage potential of the platform
-New proteins and partnerships